Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial
暂无分享,去创建一个
Won Ki Lee | Paisan Ruamviboonsuk | T. Wong | T. Lim | P. Ruamviboonsuk | A. Koh | W. Lee | T. Lai | Kanji Takahashi | C. Feller | Colin S. Tan | Tien Y Wong | Kanji Takahashi | Philippe Margaron | Timothy Y Y Lai | Adrian Koh | Lee-Jen Chen | Colin S Tan | Chrystel Feller | Tock H Lim | P. Margaron | Lee‐Jen Chen | Paisan Ruamviboonsuk | T. Wong | T. Wong | T. Wong
[1] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[2] S. C. Lee,et al. Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy , 2008, Ophthalmologica.
[3] J. Cunha-Vaz,et al. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.
[4] S. C. Lee,et al. Polypoidal Choroidal Vasculopathy in Korean Patients with Large Submacular Hemorrhage , 2007, Yonsei medical journal.
[5] T. Wong,et al. Systemic, Ocular and Genetic Risk Factors for Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Singaporeans , 2017, Scientific Reports.
[6] Quan Dong Nguyen,et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.
[7] L. Yannuzzi,et al. Polypoidal choroidal vasculopathy. , 2002, Ophthalmology clinics of North America.
[8] A. Tsujikawa,et al. Chorioretinal anastomosis after photodynamic therapy for polypoidal choroidal vasculopathy , 2008, International Ophthalmology.
[9] K. Fujita,et al. Role of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy , 2007, Japanese Journal of Ophthalmology.
[10] Won Ki Lee,et al. EVEREST STUDY: Efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy , 2012, Retina.
[11] U. Schmidt-Erfurth,et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. , 2012, Ophthalmology.
[12] H. Kohno,et al. Three‐year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy , 2016, Acta ophthalmologica.
[13] R. Guymer,et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. , 2011, Ophthalmology.
[14] L. Yannuzzi,et al. IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV) , 2012, Retina.
[15] T. Stokkermans,et al. Treatment of age-related macular degeneration. , 2000, Clinical eye and vision care.
[16] Jennifer K. Sun,et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. , 2011, Ophthalmology.
[17] S. Lee,et al. The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy , 2008, Korean journal of ophthalmology : KJO.
[18] I. Maruko,et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. , 2007, American journal of ophthalmology.
[19] T. Iida,et al. INTRAVITREAL RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY WITH RECURRENT OR RESIDUAL EXUDATION , 2011, Retina.
[20] L. Yannuzzi,et al. Polypoidal choroidal vasculopathy: a review. , 2010, Survey of ophthalmology.
[21] T. Wong,et al. Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese persons. , 2011, Ophthalmology.
[22] T. Iida. Polypoidal choroidal vasculopathy with an appearance similar to classic choroidal neovascularisation on fluorescein angiography , 2007, British Journal of Ophthalmology.
[23] T. Lim,et al. Polypoidal choroidal vasculopathy: an angiographic discussion , 2010, Eye.
[24] T. Lai,et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. , 2004, Ophthalmology.
[25] Ching-Yu Cheng,et al. Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai Eye Study. , 2008, Investigative ophthalmology & visual science.
[26] M. Matsumura,et al. Polypoidal choroidal vasculopathy: natural history. , 2002, American journal of ophthalmology.
[27] P. Ruamviboonsuk,et al. POLYPOIDAL CHOROIDAL VASCULOPATHY: Evidence-Based Guidelines for Clinical Diagnosis and Treatment , 2013, Retina.
[28] A. Eller,et al. The Therapeutic Effects of Intravitreal Bevacizumab in a Patient with Recalcitrant Idiopathic Polypoidal Choroidal Vasculopathy , 2007, Seminars in ophthalmology.
[29] Allen C Ho,et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.
[30] T. Hikichi,et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. , 2012, American journal of ophthalmology.
[31] L. Yeung,et al. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results , 2009, British Journal of Ophthalmology.
[32] J. Slakter,et al. INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY , 1995, Retina.
[33] D. Guo,et al. Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis. , 2015, International journal of ophthalmology.
[34] J. García-Feijóo,et al. Short-Term Anatomic Effect of Ranibizumab for Polypoidal Choroidal Vasculopathy , 2008, European journal of ophthalmology.
[35] Y. Tano,et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. , 2010, Ophthalmology.
[36] A. Tsujikawa,et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. , 2007, American journal of ophthalmology.
[37] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[38] M. Mauget-Faÿsse,et al. Photodynamic Therapy with Verteporfin in the Treatment of Exudative Idiopathic Polypoidal Choroidal Vasculopathy , 2006, European journal of ophthalmology.
[39] Y. Hirami,et al. Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. , 2006, American journal of ophthalmology.
[40] Julie F Pallant,et al. The Impact of Vision Impairment Questionnaire: an evaluation of its measurement properties using Rasch analysis. , 2006, Investigative ophthalmology & visual science.
[41] S. Byeon,et al. Clinical features and follow‐up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy , 2010, Acta ophthalmologica.
[42] Xiulan Zhang,et al. Combined Intravitreal Anti-VEGF and Photodynamic Therapy versus Photodynamic Monotherapy for Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis of Comparative Studies , 2014, PloS one.
[43] Y. Tano,et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy , 2007, British Journal of Ophthalmology.
[44] M. Matsumura,et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. , 2003, Archives of ophthalmology.
[45] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[46] J. Lim,et al. The Effect of Intravitreal Bevacizumab in Patients with Acute Central Serous Chorioretinopathy , 2010, Korean journal of ophthalmology : KJO.
[47] M. Mandai,et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. , 2013, American journal of ophthalmology.
[48] T. Lai,et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy , 2008, British Journal of Ophthalmology.
[49] Akira Negi,et al. Polypoidal Choroidal Vasculopathy: Clinical Features and Genetic Predisposition , 2013, Ophthalmologica.
[50] T. Matsuo,et al. Surgical treatment of submacular hemorrhage associated with idiopathic polypoidal choroidal vasculopathy. , 1999, American journal of ophthalmology.
[51] C. Cheung,et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians , 2016, Progress in Retinal and Eye Research.
[52] P. Kaiser,et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. , 2012, Ophthalmology.
[53] T. Lim,et al. IMPROVED SPECIFICITY OF POLYPOIDAL CHOROIDAL VASCULOPATHY DIAGNOSIS USING A MODIFIED EVEREST CRITERIA , 2015, Retina.
[54] T. Lim,et al. EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study , 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.
[55] J. Y. Kim,et al. INTRAVITREAL RANIBIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR TREATING POLYPOIDAL CHOROIDAL VASCULOPATHY , 2011, Retina.
[56] Raymond L. M. Wong,et al. Polypoidal Choroidal Vasculopathy: An Update on Therapeutic Approaches , 2013, Journal of ophthalmic & vision research.
[57] W. Lee,et al. Photodynamic therapy for polypoidal choroidal vasculopathy: Vaso-occlusive effect on the branching vascular network and origin of recurrence , 2008, Japanese Journal of Ophthalmology.
[58] M. Matsumura,et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy , 2004, British Journal of Ophthalmology.
[59] J. Keeffe,et al. Assessment of the impact of vision impairment. , 2002, Investigative ophthalmology & visual science.
[60] M. Tadarati,et al. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study , 2010, British Journal of Ophthalmology.
[61] Y. Tano,et al. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.
[62] Augustinus Laude,et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease? , 2010, Progress in Retinal and Eye Research.
[63] W. Freeman,et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.
[64] G. Kokame. Polypoidal choroidal vasculopathy--an important diagnosis to make with therapeutic implications. , 2012, Retina.
[65] L A Yannuzzi,et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. , 1999, Archives of ophthalmology.
[66] Philip J Rosenfeld,et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.
[67] K. Freund,et al. POLYPOIDAL CHOROIDAL VASCULOPATHY: Simultaneous Indocyanine Green Angiography and Eye-Tracked Spectral Domain Optical Coherence Tomography Findings , 2012, Retina.
[68] T. Wong,et al. UNDERSTANDING INDOCYANINE GREEN ANGIOGRAPHY IN POLYPOIDAL CHOROIDAL VASCULOPATHY: The Group Experience With Digital Fundus Photography and Confocal Scanning Laser Ophthalmoscopy , 2014, Retina.
[69] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[70] M. Mandai,et al. HEMORRHAGIC COMPLICATIONS AFTER PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY , 2007, Retina.
[71] E. Neoh,et al. Polypoidal choroidal vasculopathy in Chinese patients , 2002, The British journal of ophthalmology.
[72] K. Choy,et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. , 2006, American journal of ophthalmology.
[73] Tock Han Lim,et al. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy , 2015, British Journal of Ophthalmology.
[74] Y. Oshima,et al. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study , 2015, Retina.
[75] M. Yuzawa,et al. The origins of polypoidal choroidal vasculopathy , 2005, British Journal of Ophthalmology.
[76] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[77] R. Obata,et al. Polypoidal Choroidal Vasculopathy and Retinochoroidal Anastomosis in Japanese Patients Eligible for Photodynamic Therapy for Exudative Age-Related Macular Degeneration , 2006, Japanese Journal of Ophthalmology.
[78] Janet L. Davis,et al. Clinicopathologic correlation of idiopathic polypoidal choroidal vasculopathy , 2002 .
[79] H. J. Cho,et al. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy , 2012, Eye.
[80] L. Yannuzzi,et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. , 1997, Archives of ophthalmology.